The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation. / Mortensen, Katrine Brandt; Gerds, Thomas Alexander; Bjerrum, Ole Weis; Lindmark, Anders; Sengeløv, Henrik; Andersen, Christen Lykkegaard.
I: Leukemia Research, Bind 38, Nr. 3, 03.2014, s. 334-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation
AU - Mortensen, Katrine Brandt
AU - Gerds, Thomas Alexander
AU - Bjerrum, Ole Weis
AU - Lindmark, Anders
AU - Sengeløv, Henrik
AU - Andersen, Christen Lykkegaard
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2014/3
Y1 - 2014/3
N2 - The prognostic significance of eosinophilia after myeloablative allogeneic stem cell transplantation (ASCT) remains to be established. Patients, whom developed chronic graft-versus-host disease (cGVHD) after ASCT, were included (n = 142). Eosinophil count was analyzed at cGVHD onset. We observed no significant association between EO and the grade of cGVHD, thrombocytopenia, nor extensive skin involvement. Importantly, we observed no significant association between cGVHD with concomitant eosinophilia and long-term clinical outcomes, and subgroup analyses revealed a considerable confounding effect of ongoing steroid treatment. In conclusion, we advocate that prognostic conclusions regarding cGVHD with concomitant eosinophilia after ASCT should be interpreted with caution.
AB - The prognostic significance of eosinophilia after myeloablative allogeneic stem cell transplantation (ASCT) remains to be established. Patients, whom developed chronic graft-versus-host disease (cGVHD) after ASCT, were included (n = 142). Eosinophil count was analyzed at cGVHD onset. We observed no significant association between EO and the grade of cGVHD, thrombocytopenia, nor extensive skin involvement. Importantly, we observed no significant association between cGVHD with concomitant eosinophilia and long-term clinical outcomes, and subgroup analyses revealed a considerable confounding effect of ongoing steroid treatment. In conclusion, we advocate that prognostic conclusions regarding cGVHD with concomitant eosinophilia after ASCT should be interpreted with caution.
KW - Adolescent
KW - Adult
KW - Blood Platelets
KW - Eosinophilia
KW - Eosinophils
KW - Female
KW - Glucocorticoids
KW - Graft vs Host Disease
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Leukemia
KW - Male
KW - Middle Aged
KW - Myeloablative Agonists
KW - Prognosis
KW - Risk Factors
KW - Skin
KW - Transplantation, Homologous
U2 - 10.1016/j.leukres.2013.12.009
DO - 10.1016/j.leukres.2013.12.009
M3 - Journal article
C2 - 24439053
VL - 38
SP - 334
EP - 339
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 3
ER -
ID: 134781183